momentum-landing-page-hero-2-072224.jpg
momentum-landing-page-hero-2-072224-mobile.jpg

Dana-Farber’s revolutionary discoveries are changing cancer treatment everywhere.

Dana-Farber has played a foundational role in more than half of the cancer drugs approved by the FDA.

Data from 2018-2022

What we do here
changes lives everywhere

When you follow the science, one thing leads to another. A new insight takes a previous breakthrough further. Thanks to our momentum of discovery, living with cancer is less of a burden, and living without cancer is a greater possibility.

One cancer discovery after another for over 75 years.

FDA Approves Dual-Action Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors, Backed by Dana-Farber Research
Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs). This represents a new standard of care ther...
Combining BCL-2 and BTK inhibitors shows promise in CLL
A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug — shows deep and durable responses in patients with chron...
FDA approves new therapy for glioma patients for first time in decades
Based on results of the phase 3 INDIGO clinical trial co-led by Dana-Farber Cancer Institute, the newly approved drug vorasidenib could delay the need for radiation and chemotherapy for patients with IDH-mutant glioma.